cetuximab [Cetuximab]

tematický
186
Termíny

Erbitux

 

C225
Erbitux
IMC C225
IMC-C225
MAb C225

Perzistentní odkaz   https://www.medvik.cz/link/D000068818
Definice

A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.

DUI
D000068818 MeSH Prohlížeč
CUI
M0422675
Historická pozn.
2016 (2000)
Veřejná pozn.
2016; CETUXIMAB was indexed under ANTIBODIES, MONOCLONAL 2000-2013; and under ANTIBODIES, MONOCLONAL, HUMANIZED 2013-2015

Povolená podhesla

AN
analýza
AD
aplikace a dávkování 37
BI
biosyntéza
CH
chemie 2
HI
dějiny
EC
ekonomika 2
PK
farmakokinetika 1
PD
farmakologie 41
PH
fyziologie
GE
genetika
IM
imunologie 1
IP
izolace a purifikace
CL
klasifikace
BL
krev
ME
metabolismus 1
UR
moč
CF
mozkomíšní mok
PO
otrava
AE
škodlivé účinky 23
TU
terapeutické užití 103
TO
toxicita 1
DE
účinky léků 1
RE
účinky záření
UL
ultrastruktura

D Chemikálie a léčiva
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 581
D12.776.124 krevní proteiny 909
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 492
D12.776.124.486.485.114 protilátky 1 815
D12.776.124.486.485.114.224 monoklonální protilátky 4 659
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 854
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 349
D12.776.124.486.485.114.224.060.313 alemtuzumab 125
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 452
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 42
D12.776.124.486.485.114.224.060.500 certolizumab pegol 47
D12.776.124.486.485.114.224.060.750 cetuximab 186
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 153
D12.776.124.486.485.114.224.060.790 gemtuzumab 16
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 263
D12.776.124.486.485.114.224.060.813 natalizumab 157
D12.776.124.486.485.114.224.060.829 nivolumab 449
D12.776.124.486.485.114.224.060.844 omalizumab 112
D12.776.124.486.485.114.224.060.860 palivizumab 12
D12.776.124.486.485.114.224.060.864 panitumumab 58
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 61
D12.776.124.486.485.114.224.060.875 trastuzumab 274
D12.776.124.486.485.114.224.060.937 ustekinumab 121
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 492
D12.776.124.790.651.114 protilátky 1 815
D12.776.124.790.651.114.224 monoklonální protilátky 4 659
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 854
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 349
D12.776.124.790.651.114.224.060.375 alemtuzumab 125
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 452
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 42
D12.776.124.790.651.114.224.060.500 certolizumab pegol 47
D12.776.124.790.651.114.224.060.750 cetuximab 186
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 153
D12.776.124.790.651.114.224.060.790 gemtuzumab 16
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 263
D12.776.124.790.651.114.224.060.813 natalizumab 157
D12.776.124.790.651.114.224.060.829 nivolumab 449
D12.776.124.790.651.114.224.060.844 omalizumab 112
D12.776.124.790.651.114.224.060.860 palivizumab 12
D12.776.124.790.651.114.224.060.864 panitumumab 58
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 61
D12.776.124.790.651.114.224.060.875 trastuzumab 274
D12.776.124.790.651.114.224.060.937 ustekinumab 121
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 492
D12.776.377.715.548.114 protilátky 1 815
D12.776.377.715.548.114.224 monoklonální protilátky 4 659
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 854
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 349
D12.776.377.715.548.114.224.200.375 alemtuzumab 125
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 452
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 42
D12.776.377.715.548.114.224.200.500 certolizumab pegol 47
D12.776.377.715.548.114.224.200.750 cetuximab 186
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 153
D12.776.377.715.548.114.224.200.790 gemtuzumab 16
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 263
D12.776.377.715.548.114.224.200.813 natalizumab 157
D12.776.377.715.548.114.224.200.829 nivolumab 449
D12.776.377.715.548.114.224.200.844 omalizumab 112
D12.776.377.715.548.114.224.200.860 palivizumab 12
D12.776.377.715.548.114.224.200.864 panitumumab 58
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 61
D12.776.377.715.548.114.224.200.875 trastuzumab 274
D12.776.377.715.548.114.224.200.937 ustekinumab 121

64Cu-DOTA-cetuximab Chemical MeSH Prohlížeč

Zpět Přidat